BCMA-Targeting Single-Domain Antibody for High-Affinity Binding

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for novel anti-BCMA antibodies with high affinity and specificity for BCMA, which is a popular immunotherapeutic target for multiple myeloma and other hematologic malignancies.

Innovation Solution

The development of an isolated antigen-binding fragment that competes for binding to BCMA protein with high affinity and specificity, utilizing a heavy chain variable region comprising specific amino acid sequences for HCDR1, HCDR2, and HCDR3.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antibodies are used, then complete antibody function is achieved, but molecular weight is large and penetration capacity is limited

Engineering Contradiction:

Improveantibody functionVSAvoidmolecular weight

Core Design Contradiction:

ReliabilityVSWeight of moving object

Solution Approach 1:

The patent segments the conventional antibody structure into a single-domain antibody (sdAb) consisting of only the heavy chain variable domain (VHH). This segmentation maintains the essential antigen-binding function while reducing molecular weight to approximately 15 kDa, enabling superior penetration capacity compared to full-sized antibodies.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent extracts only the functional heavy chain variable domain from the complete antibody structure, discarding the constant regions and light chains. This extraction preserves the antigen-binding capability while eliminating unnecessary structural components, achieving both small size and complete function.

Inventive Principle:

Principle #2Taking out (Extraction)

2Weight of moving object

If single-domain antibodies are used, then molecular weight is small and penetration capacity is improved, but binding affinity and specificity need to be optimized

Engineering Contradiction:

Improvemolecular weightVSAvoidbinding affinity and specificity

Core Design Contradiction:

Weight of moving objectVSReliability

Solution Approach 1:

The patent optimizes the local quality of the VHH domain by selecting and engineering specific complementarity-determining regions (CDRs) with high affinity for BCMA. The HCDR1, HCDR2, and HCDR3 regions are specifically designed to maximize binding strength and specificity while maintaining the small molecular weight advantage of sdAbs.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the amino acid sequence parameters of the VHH domain, particularly in the CDR regions, to achieve optimal binding affinity. By modifying specific residues in HCDR1-3, the patent achieves high-affinity binding to BCMA with KD values in the nanomolar range, overcoming the typical limitation of smaller antibody fragments.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If novel anti-BCMA antibodies are developed, then affinity and specificity for BCMA are improved, but development complexity increases

Engineering Contradiction:

Improveaffinity and specificity for BCMAVSAvoiddevelopment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses a template-based approach by copying and adapting known VHH structural frameworks and CDR sequencing patterns that have proven successful for BCMA binding. This copying strategy reduces development complexity by leveraging established designs rather than de novo engineering, while still achieving high affinity and specificity.

Inventive Principle:

Principle #26Copying

Data Source

PatentUS20250171550A1BCMA-targeting single-domain antibody

Publication Date: 2025.05.29 NINGBO T MAXIMUM BIOPHARMACEUTICALS CO LTD

AI summary

A BCMA-targeting single-domain antibody, which has high affinity for BCMA protein. A use of the single-domain antibody in preparing a medicament for preventing or treating a disease or condition.